ArticleProceedings of the National Academy of Sciences of the United States of America2016

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.

Wei Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.